Iovance Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and thank you for joining us today. My name is Malika, and I'm an associate in JPMorgan's Healthcare Group. (Operator Instructions)
With that, I'm pleased to introduce you to Fred Vogt, Interim CEO and General Counsel; Jean-Marc Bellemin, CFO; and Madan Jagasia, SVP of Medical Affairs at Iovance Biotherapeutics. I know that they are all very excited to tell you about their story, so we'll turn it over to Fred and his team.
Thank you, Malika, and thank you to the JPMorgan conference and organizers for inviting us today. My name is Fred Vogt. I'm the interim CEO at Iovance, and it's my pleasure to present to you on the company and some of the great things we're doing in immuno-oncology.
On Slide 2 of our presentation, you'll see our forward-looking statements. Just be aware of this. I'll be making forward-looking statements today in our presentation.
On Slide 3, by the numbers, Iovance is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |